BAZ2A

Bromodomain adjacent to zinc finger domain protein 2A · Q9UIF9 · BAZ2A on Sugi Atlas →

10,786 patent compounds predicted against BAZ2A, 6,171 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3160202	0.43	7/20
SCHEMBL3897812	0.43	6/20
SCHEMBL4791760	0.38	6/20
Hydrochloric Acid (SCHEMBL2516985)	0.51	5/20
Propionic Acid (SCHEMBL4577942)	0.49	5/20
SCHEMBL1221964	0.47	4/20
SCHEMBL2826722	0.41	4/20
Hydrochloric Acid (SCHEMBL1119909)	0.54	3/20
Hydrochloric Acid (SCHEMBL2584196)	0.48	3/20
SCHEMBL4714535	0.47	3/20
SCHEMBL4261249	0.46	3/20
SCHEMBL1303268	0.41	3/20
Hydrochloric Acid (SCHEMBL2273378)	0.41	3/20
SCHEMBL3794284	0.40	3/20
SCHEMBL4262991	0.40	3/20
SCHEMBL367200	0.40	3/20
Bromide (SCHEMBL2969089)	0.39	3/20
SCHEMBL4705312	0.38	3/20
Hydrochloric Acid (SCHEMBL1583183)	0.36	3/20
SCHEMBL1228518	0.52	2/20

Clinical trials — most relevant to BAZ2A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD	PHASE3	COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma	PHASE2	COMPLETED
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
Chidamide Combined With Toripalimab in Sarcoma	PHASE2	COMPLETED
Vorinostat in Children	PHASE1/PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Safety and Pharmacokinetic Profile of CKD-581	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML	PHASE1	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage	nan	ENROLLING_BY_INVITATION
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a BAZ2A binder may also engage these)

Protein	Name	Similarity
Q91YE5	—	1.000	Q91YE5 →
Q8BZ32	—	0.999	Q8BZ32 →
B7ZS37	—	0.997	B7ZS37 →
Q8R5I7	—	0.996	Q8R5I7 →
Q8BHZ4	—	0.996	Q8BHZ4 →
Q9JL04	—	0.996	Q9JL04 →
Q05A80	—	0.996	Q05A80 →
CECR2	Chromatin remodeling regulator CECR2	0.995	landscape →
Q9H4I2	—	0.995	Q9H4I2 →
E1BE02	—	0.995	E1BE02 →
Q63755	—	0.995	Q63755 →
KDM3B	Lysine-specific demethylase 3B	0.994	landscape →
Q8K0T0	—	0.994	Q8K0T0 →
PHF20	PHD finger protein 20	0.993	landscape →
Q92610	—	0.993	Q92610 →
Q76N89	—	0.993	Q76N89 →
MIDEAS	Mitotic deacetylase-associated SANT domain protein	0.993	landscape →
NFRKB	Nuclear factor related to kappa-B-binding protein	0.993	landscape →
Q6PCQ0	—	0.993	Q6PCQ0 →
Q14865	—	0.993	Q14865 →
O18805	—	0.993	O18805 →
Q9Y6A5	—	0.993	Q9Y6A5 →
Q8C0C0	—	0.992	Q8C0C0 →
P48382	—	0.992	P48382 →
Q76L83	—	0.992	Q76L83 →
Q99ME3	—	0.992	Q99ME3 →
Q8CCJ9	—	0.992	Q8CCJ9 →
Q8CCG4	—	0.992	Q8CCG4 →
Q2KHR2	—	0.992	Q2KHR2 →
O35914	—	0.992	O35914 →